Showing results (241-250 of 326) with videos related to

Sort By:
Pageof 33
International Journal of Radiation Oncology, Biology, Physics|July 30, 1994
Alternating irradiation and chemotherapy in stage III A and B nonsmall cell lung cancer: report of a cancer and Leukemia Group B phase II study 8636S L Seagren, J E Herndon, J R Baeker, et al.
Lung Cancer (Amsterdam, Netherlands)|February 13, 2001
Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group BH L Kindler, F Millard, J E Herndon, et al.
Oncology (Williston Park, N.Y.)|April 17, 2001
Irinotecan/gemcitabine combination chemotherapy in pancreatic cancerC M Rocha Lima, C A Sherman, F J Brescia, et al.
Cancer|October 15, 1985
Applications and limitations of peripheral blood lymphocyte immunoglobulin light chain analysis in the evaluation of non-Hodgkin's lymphomaR E Sobol, R O Dillman, H Collins, et al.
Chest|March 27, 1998
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group BJ E Herndon, M R Green, A P Chahinian, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|March 5, 2014
BSACI guideline for the diagnosis and management of cow's milk allergyD Luyt, H Ball, N Makwana, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 1993
The type 1 human immunodeficiency virus Tat binding protein is a transcriptional activator belonging to an additional family of evolutionarily conserved genesB Ohana, P A Moore, S M Ruben, et al.
Seminars in Oncology|August 1, 1997
A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancerH B Neill, A A Miller, G H Clamon, et al.
Molecular Cell|December 9, 1998
Broad, but not universal, transcriptional requirement for yTAFII17, a histone H3-like TAFII present in TFIID and SAGAL M Apone, C A Virbasius, F C Holstege, et al.
Cancer|November 26, 1999
Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group BH L Kindler, C P Belani, J E Herndon, et al.
Pageof 33